Corcept Therapeutics, Inc. (CORT)
87.13
+1.82
(+2.13%)
USD |
NASDAQ |
Dec 11, 16:00
87.95
+0.82
(+0.94%)
After-Hours: 20:00
Corcept Therapeutics Research and Development Expense (TTM): 260.35M for Sept. 30, 2025
Research and Development Expense (TTM) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (TTM) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (TTM) Benchmarks
| Amgen, Inc. | 6.828B |
| Gilead Sciences, Inc. | 5.734B |
| LeMaitre Vascular, Inc. | 14.22M |
| United Therapeutics Corp. | 544.30M |
| Vertex Pharmaceuticals, Inc. | 3.954B |